Results
- Showing results for:
- Reset all filters
Search results
-
Conference paperMullish BH, Marchesi J, Pass DA, et al., 2021,
DAILY PROBIOTIC USE IS ASSOCIATED WITH A REDUCED RATE OF UPPER RESPIRATORY TRACT SYMPTOMS IN OVERWEIGHT AND OBESE PEOPLE
, Society-for-Surgery-of-the-Alimentary-Tract Annual Meeting at Digestive Disease Week (DDW), Publisher: W B SAUNDERS CO-ELSEVIER INC, Pages: S150-S150, ISSN: 0016-5085 -
Conference paperRadhakrishnan ST, Mullish BH, Gallagher K, et al., 2021,
RECTAL SWABS AS A VIABLE ALTERNATIVE TO FECAL SAMPLING FOR THE ANALYSIS OF GUT MICROBIOME FUNCTIONALITY AS WELL AS COMPOSITION
, Society-for-Surgery-of-the-Alimentary-Tract Annual Meeting at Digestive Disease Week (DDW), Publisher: W B SAUNDERS CO-ELSEVIER INC, Pages: S733-S733, ISSN: 0016-5085 -
Conference paperMartinez-Gili L, Mullish BH, Correia G, et al., 2021,
A distinctive signature of fecal bile acids and other novel metabolites accompanying recurrence after primary clostridioides difficile infection
, Society for Surgery of the Alimentary Tract Annual Meeting at Digestive Disease Week (DDW), Publisher: Elsevier, Pages: S368-S368, ISSN: 0016-5085 -
Conference paperAllegretti JR, Mullish BH, Marchesi J, et al., 2021,
ASSOCIATION BETWEEN NOVEL METABOLOMIC BIOMARKERS AND C.DIFFICILE RECURRENCE
, Society-for-Surgery-of-the-Alimentary-Tract Annual Meeting at Digestive Disease Week (DDW), Publisher: W B SAUNDERS CO-ELSEVIER INC, Pages: S369-S369, ISSN: 0016-5085 -
Conference paperMullish BH, Innes AJ, Ghani R, et al., 2021,
FECAL MICROBIOTA TRANSPLANT PRIOR TO ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT IN PATIENTS COLONIZED WITH MULTI-DRUG RESISTANT ORGANISMS IS ASSOCIATED WITH IMPROVED SURVIVAL
, Society-for-Surgery-of-the-Alimentary-Tract Annual Meeting at Digestive Disease Week (DDW), Publisher: W B SAUNDERS CO-ELSEVIER INC, Pages: S168-S169, ISSN: 0016-5085 -
Journal articleGhani R, Mullish BH, McDonald JAK, et al., 2021,
Disease prevention not decolonization – a model for fecal microbiota transplantation in patients colonized with multidrug-resistant organisms
, Clinical Infectious Diseases, Vol: 72, Pages: 1444-1447, ISSN: 1058-4838Fecal microbiota transplantation (FMT) yields variable intestinal decolonization results for multidrug-resistant organisms (MDROs). This study showed significant reductions in antibiotic duration, bacteremia and length of stay in 20 patients colonized/ infected with MDRO receiving FMT (compared to pre-FMT history, and a matched group not receiving FMT), despite modest decolonization rates.
-
Journal articleMullish BH, Alexander JL, Segal JP, 2021,
Microbiota and faecal microbiota transplant
, Microbiota in Health and Disease, Vol: 3, ISSN: 2704-8845As the range of disease states associated with the gut microbiome expands - and the mechanistic links between the gut microbiome and host physiology further deepens – so interest also grows in microbiome manipulation as medical therapy. In particular, bolstered by its established role in recurrent C. difficile infection (and promising results in other conditions), faecal microbiota transplant (FMT) has remained of growing global focus. This article reviews the key FMT-based studies published between April 2020 - March 2021. While the COVID-19 pandemic was the dominant challenge of the year, important FMT trials of interest were published for patients with a range of different conditions. The emergence of ‘next generation’ microbiome therapeutics offers an additional perspective and new opportunities within the field.
-
Journal articleGupta S, Mullish BH, Allegretti JR, 2021,
Fecal microbiota transplantation: the evolving risk landscape
, American Journal of Gastroenterology, Vol: 116, Pages: 647-656, ISSN: 0002-9270Fecal microbiota transplantation (FMT) has been recommended in clinical guidelines for the treatment for recurrent Clostridioides difficile infection (CDI). However, it is considered investigational by most regulatory agencies. As the adoption of FMT increased from a small group of CDI experts alone to more widespread use, there has been a corresponding increase in concern regarding potential risk. FMT is largely considered a safe procedure, though risks described range from mild gastrointestinal symptoms to serious infection. Currently, there is variability in how ‘FMT’ is characterized specifically with regards to testing approach, which, in turn, impacts the risk profile. This has been highlighted by the rare cases of multidrug-resistant organisms, Shiga toxin-producing E. coli and enteropathogenic E. coli recently reported, where these organisms were not screened. These cases have prompted additional screening mandates from the FDA, which has maintained its policy of enforcement discretion for the use of FMT for CDI not responding to standard therapy. Here, we examine the evolving risk landscape of FMT.
-
Conference paperEdwards L, Woodhouse C, Mullish BH, et al., 2021,
Faecal microbiota transplantation improves intestinal barrier function and modulates mucosal IL-17 immunity in patients with advanced cirrhosis
, ILC 2021, Publisher: Elsevier, Pages: S220-S221, ISSN: 0168-8278 -
Journal articleMullish BH, Marchesi JR, McDonald JAK, et al., 2021,
Probiotics reduce self-reported symptoms of upper respiratory tract infection in overweight and obese adults: should we be considering probiotics during viral pandemics?
, Gut Microbes, Vol: 13, Pages: 1-9, ISSN: 1949-0976Gut microbiome manipulation to alter the gut-lung axis may potentially protect humans against respiratory infections, and clinical trials of probiotics show promise in this regard in healthy adults and children. However, comparable studies are lacking in overweight/obese people, who have increased risks in particular of viral upper respiratory tract infections (URTI). This Addendum further analyses our recent placebo-controlled trial of probiotics in overweight/obese people (focused initially on weight loss) to investigate the impact of probiotics upon the occurrence of URTI symptoms. As well as undergoing loss of weight and improvement in certain metabolic parameters, study participants taking probiotics experienced a 27% reduction in URTI symptoms versus control, with those ≥45 years or BMI ≥30 kg/m2 experiencing greater reductions. This symptom reduction is apparent within 2 weeks of probiotic use. Gut microbiome diversity remained stable throughout the study in probiotic-treated participants. Our data provide support for further trials to assess the potential role of probiotics in preventing viral URTI (and possibly also COVID-19), particularly in overweight/obese people.
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.
General enquiries
For any enquiries about the Microbiome Network at Imperial, please contact: